
Latin America Tumor Ablation Market Report and Forecast 2024-2032
Description
Latin America Tumor Ablation Market Report and Forecast 2024-2032
Latin America Tumor Ablation Market Report and Forecast 2024-2032
Latin America Tumor Ablation Market Outlook
The global tumor ablation market size was valued at USD 1.9 billion in 2023, with Latin America holding a significant market share. The market is driven by the rising introduction of advanced technologies in tumor ablation. It is expected to grow at a CAGR of 12.90% during the forecast period of 2024-2032, with the values likely to attain USD 6.3 billion by 2032.
Key Takeaways
- Recent data reveals that 9 in 10 of the most populous nations in Latin America will observe at least a 64% increase in cancer patients by 2040 . The high cancer incidence is expected to directly impact market demand for this minimally invasive technique.
- One of the major Latin America tumor ablation market trends is the increased initiatives by both public and private organizations to spread awareness about cancer treatment strategies. In October 2023 , the Pan American Health Organization (PAHO) and the International Agency for Research on Cancer (IARC) announced the first edition of Latin America and the Caribbean Code Against Cancer with the objective of reducing cancer cases in the region.
- The market is also influenced by the minimally invasive nature of tumor ablation therapy which fuels its adoption rate due to shorter recovery times and fewer complications compared to traditional surgeries to treat cancer.
Tumor ablation is a medical procedure that is utilized to destroy cancer cells in a tumor in various parts of the body, such as the liver, kidney, and bone. Some common tumor ablation approaches include radiofrequency ablation (RFA) and cryoablation. This technique can help in localized destruction of cancerous cells without the need for invasive surgery. Due to its minimally invasive nature, this technique is associated with shorter recovery times and fewer complications than traditional surgeries. Hence, the Latin America tumor ablation market demand is expected to witness a surge in the coming years.
Latin America has a significant burden of cancer which can be attributed to the rising aging populations, lifestyle changes, and genetic factors. Recent data reveals that 9 in 10 of the most populous nations in Latin America will observe at least a 64% increase in cancer patients by 2040. Further, it is estimated that nearly 1 million new cancer cases will occur in Brazil each year, which indicates the urgent need for effective cancer treatment options including tumor ablation techniques for managing different types of cancer. Consequently, the high cancer incidence is expected to drive the Latin America tumor ablation market growth.
The market is also influenced by the increased initiatives by both public and private organizations to tackle the growing cancer burden and spread awareness about its management strategies including advanced procedures like tumor ablation. For instance, in October 2023, the Pan American Health Organization (PAHO) and the International Agency for Research on Cancer (IARC) announced the first edition of Latin America and the Caribbean Code Against Cancer with the objective of reducing cancer cases in the region. As a part of the World Code Against Cancer, the new Code will offer latest recommendations based on the most recent scientific evidence, influencing changes in health policies and behaviors to prevent cancer. Such initiatives are likely to heighten public awareness regarding the benefits of tumor ablation therapy and enhance its adoption rate, which is poised to augment the market share.
Latin America Tumor Ablation Market Segmentation
Market Breakup by Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation Ablation
- Other Ablation Technologies
- Kidney Cancer
- Liver Cancer
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Bone Cancer
- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
- Hospitals
- Cancer Specialty Clinics
- Others
- Brazil
- Argentina
- Mexico
- Others
The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Medtronic
- Boston Scientific Corporation
- AngioDynamics
- Mermaid Medical
- HealthTronics
- Galil Medical Inc.
- EDAP TMS S.A.
- Misonix, Inc.
- NeuWave Medical, Inc.
- SonaCare Medical
FAQs
- What is the Latin America tumor ablation market forecast outlook for 2024-2032?
- What are the major factors aiding the Latin America tumor ablation market demand?
- What are the major Latin America tumor ablation market trends?
- What is the market segmentation based on the type?
- What is the market breakup by therapeutic area?
- What are the major end users of the market?
- What are the applications of the market?
- What is the market segmentation by countries?
- Who are the key players involved in the Latin America tumor ablation market?
Meta description
The Latin America tumor ablation market is poised for growth, driven by the expansion of the global market, which was valued at USD 1.9 billion in 2023 and is projected to grow at a CAGR of 14.2% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Latin America Tumor Ablation Market Overview
- 3.1 Latin America Tumor Ablation Market Historical Value (2017-2023)
- 3.2 Latin America Tumor Ablation Market Forecast Value (2024-2032)
- 4 Latin America Tumor Ablation Market Landscape*
- 4.1 Latin America Tumor Ablation: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Latin America Tumor Ablation: Product Landscape
- 4.2.1 Analysis by Technology
- 4.2.2 Analysis by Application
- 5 Latin America Tumor Ablation Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Latin America Tumor Ablation Market Segmentation (2017-2032)
- 6.1 Latin America Tumor Ablation Market (2017-2032) by Technology
- 6.1.1 Market Overview
- 6.1.2 Radiofrequency Ablation
- 6.1.3 Microwave Ablation
- 6.1.4 Cryoablation
- 6.1.5 Irreversible Electroporation Ablation
- 6.1.6 Other Ablation Technologies
- 6.2 Latin America Tumor Ablation Market (2017-2032) by Application
- 6.2.1 Market Overview
- 6.2.2 Kidney Cancer
- 6.2.3 Liver Cancer
- 6.2.4 Breast Cancer
- 6.2.5 Lung Cancer
- 6.2.6 Prostate Cancer
- 6.2.7 Bone Cancer
- 6.3 Latin America Tumor Ablation Market (2017-2032) by Mode of Treatment
- 6.3.1 Market Overview
- 6.3.2 Surgical Ablation
- 6.3.3 Laparoscopic Ablation
- 6.3.4 Percutaneous Ablation
- 6.4 Latin America Tumor Ablation Market (2017-2032) by End User
- 6.4.1 Market Overview
- 6.4.2 Hospitals
- 6.4.3 Cancer Specialty Clinics
- 6.4.4 Others
- 6.5 Latin America Tumor Ablation Market (2017-2032) by Country
- 6.5.1 Market Overview
- 6.5.2 Brazil
- 6.5.3 Argentina
- 6.5.4 Mexico
- 6.5.5 Others
- 7 Brazil Tumor Ablation Market (2017-2032)
- 7.1 Brazil Tumor Ablation Market (2017-2032) by Technology
- 7.1.1 Market Overview
- 7.1.2 Radiofrequency Ablation
- 7.1.3 Microwave Ablation
- 7.1.4 Cryoablation
- 7.1.5 Irreversible Electroporation Ablation
- 7.1.6 Other Ablation Technologies
- 7.2 Brazil Tumor Ablation Market (2017-2032) by Application
- 7.2.1 Market Overview
- 7.2.2 Kidney Cancer
- 7.2.3 Liver Cancer
- 7.2.4 Breast Cancer
- 7.2.5 Lung Cancer
- 7.2.6 Prostate Cancer
- 7.2.7 Bone Cancer
- 7.3 Brazil Tumor Ablation Market (2017-2032) by Mode of Treatment
- 7.3.1 Market Overview
- 7.3.2 Surgical Ablation
- 7.3.3 Laparoscopic Ablation
- 7.3.4 Percutaneous Ablation
- 7.4 Brazil Tumor Ablation Market (2017-2032) by End User
- 7.4.1 Market Overview
- 7.4.2 Hospitals
- 7.4.3 Cancer Specialty Clinics
- 7.4.4 Others
- 8 Argentina Tumor Ablation Market (2017-2032)
- 8.1 Argentina Tumor Ablation Market (2017-2032) by Technology
- 8.1.1 Market Overview
- 8.1.2 Radiofrequency Ablation
- 8.1.3 Microwave Ablation
- 8.1.4 Cryoablation
- 8.1.5 Irreversible Electroporation Ablation
- 8.1.6 Other Ablation Technologies
- 8.2 Argentina Tumor Ablation Market (2017-2032) by Application
- 8.2.1 Market Overview
- 8.2.2 Kidney Cancer
- 8.2.3 Liver Cancer
- 8.2.4 Breast Cancer
- 8.2.5 Lung Cancer
- 8.2.6 Prostate Cancer
- 8.2.7 Bone Cancer
- 8.3 Argentina Tumor Ablation Market (2017-2032) by Mode of Treatment
- 8.3.1 Market Overview
- 8.3.2 Surgical Ablation
- 8.3.3 Laparoscopic Ablation
- 8.3.4 Percutaneous Ablation
- 8.4 Argentina Tumor Ablation Market (2017-2032) by End User
- 8.4.1 Market Overview
- 8.4.2 Hospitals
- 8.4.3 Cancer Specialty Clinics
- 8.4.4 Others
- 9 Mexico Tumor Ablation Market (2017-2032)
- 9.1 Mexico Tumor Ablation Market (2017-2032) by Technology
- 9.1.1 Market Overview
- 9.1.2 Radiofrequency Ablation
- 9.1.3 Microwave Ablation
- 9.1.4 Cryoablation
- 9.1.5 Irreversible Electroporation Ablation
- 9.1.6 Other Ablation Technologies
- 9.2 Mexico Tumor Ablation Market (2017-2032) by Application
- 9.2.1 Market Overview
- 9.2.2 Kidney Cancer
- 9.2.3 Liver Cancer
- 9.2.4 Breast Cancer
- 9.2.5 Lung Cancer
- 9.2.6 Prostate Cancer
- 9.2.7 Bone Cancer
- 9.3 Mexico Tumor Ablation Market (2017-2032) by Mode of Treatment
- 9.3.1 Market Overview
- 9.3.2 Surgical Ablation
- 9.3.3 Laparoscopic Ablation
- 9.3.4 Percutaneous Ablation
- 9.4 Mexico Tumor Ablation Market (2017-2032) by End User
- 9.4.1 Market Overview
- 9.4.2 Hospitals
- 9.4.3 Cancer Specialty Clinics
- 9.4.4 Others
- 10 Regulatory Framework
- 11 Funding and Investment Analysis
- 11.1 Analysis by Funding Instances
- 11.2 Analysis by Type of Funding
- 11.3 Analysis by Funding Amount
- 11.4 Analysis by Leading Players
- 11.5 Analysis by Leading Investors
- 11.6 Analysis by Geography
- 12 Partnership and Collaborations Analysis
- 12.1 Analysis by Partnership Instances
- 12.2 Analysis by Type of Partnership
- 12.3 Analysis by Leading Players
- 12.4 Analysis by Geography
- 13 Supplier Landscape
- 13.1 Market Share by Top 5 Companies
- 13.2 Medtronic
- 13.2.1 Financial Analysis
- 13.2.2 Product Portfolio
- 13.2.3 Demographic Reach and Achievements
- 13.2.4 Mergers and Acquisitions
- 13.2.5 Certifications
- 13.3 Boston Scientific Corporation
- 13.3.1 Financial Analysis
- 13.3.2 Product Portfolio
- 13.3.3 Demographic Reach and Achievements
- 13.3.4 Mergers and Acquisitions
- 13.3.5 Certifications
- 13.4 Angiodynamics
- 13.4.1 Financial Analysis
- 13.4.2 Product Portfolio
- 13.4.3 Demographic Reach and Achievements
- 13.4.4 Mergers and Acquisitions
- 13.4.5 Certifications
- 13.5 Mermaid Medical
- 13.5.1 Financial Analysis
- 13.5.2 Product Portfolio
- 13.5.3 Demographic Reach and Achievements
- 13.5.4 Mergers and Acquisitions
- 13.5.5 Certifications
- 13.6 HealthTronics
- 13.6.1 Financial Analysis
- 13.6.2 Product Portfolio
- 13.6.3 Demographic Reach and Achievements
- 13.6.4 Mergers and Acquisitions
- 13.6.5 Certifications
- 13.7 Galil Medical Inc.
- 13.7.1 Financial Analysis
- 13.7.2 Product Portfolio
- 13.7.3 Demographic Reach and Achievements
- 13.7.4 Mergers and Acquisitions
- 13.7.5 Certifications
- 13.8 EDAP TMS S.A.
- 13.8.1 Financial Analysis
- 13.8.2 Product Portfolio
- 13.8.3 Demographic Reach and Achievements
- 13.8.4 Mergers and Acquisitions
- 13.8.5 Certifications
- 13.9 Misonix, Inc.
- 13.9.1 Financial Analysis
- 13.9.2 Product Portfolio
- 13.9.3 Demographic Reach and Achievements
- 13.9.4 Mergers and Acquisitions
- 13.9.5 Certifications
- 13.10 Neuwave Medical, Inc.
- 13.10.1 Financial Analysis
- 13.10.2 Product Portfolio
- 13.10.3 Demographic
- 13.10.4 Mergers and Acquisitions
- 13.10.5 Certifications
- 13.11 SonaCare Medical
- 13.11.1 Financial Analysis
- 13.11.2 Product Portfolio
- 13.11.3 Demographic Reach and Achievements
- 13.11.4 Mergers and Acquisitions
- 13.11.5 Certifications
- 14 Latin America Tumor Ablation Market – Distribution Model (Additional Insight)
- 14.1 Overview
- 14.2 Potential Distributors
- 14.3 Key Parameters for Distribution Partner Assessment
- 15 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 16 Company Competitiveness Analysis (Additional Insight)
- 16.1 Very Small Companies
- 16.2 Small Companies
- 16.3 Mid-Sized Companies
- 16.4 Large Companies
- 16.5 Very Large Companies
- 17 Payment Methods (Additional Insight)
- 17.1 Government Funded
- 17.2 Private Insurance
- 17.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.